Study Vit D3/calcifediol Treatment for Covid-19

Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study

Hightlights

-The vitamin D endocrine system have a variety of actions on cells and tissues involved in COVID-19 progression.

-Early calcifediol (25-hydroxyvitamin D) treatment to hospitalized COVID-19 patients significantly reduced intensive care unit admissions-Calcifediol seems to be able to reduce severity of the COVID-19.

• Calcifediol seems to be able to reduce severity of the disease.

Objective

The vitamin D endocrine system may have a variety of actions on cells and tissues involved in COVID-19 progression especially by decreasing the Acute Respiratory Distress Syndrome. Calcifediol can rapidly increase serum 25OHD concentration. We therefore evaluated the effect of calcifediol treatment, on Intensive Care Unit Admission and Mortality rate among Spanish patients hospitalized for COVID-19.

Design

Parallel pilot randomized open label, double-masked clinical trial.

Setting

University hospital setting (Reina Sofia University Hospital, Córdoba Spain.)

Participants

76 consecutive patients hospitalized with COVID-19 infection, clinical picture of acute respiratory infection, confirmed by a radiographic pattern of viral pneumonia and by a positive SARS-CoV-2 PCR with CURB65 severity scale (recommending hospital admission in case of total score 1).

moar

https://www.sciencedirect.com/science/article/pii/S0960076020302764?via%3Dihub